Schizophrenia Research Trends

NMDA Receptor Hypofunction in Schizophrenia: From Mouse to Man 113Mastropaolo J, Rosse RB, Deutsch SI. Anabasine, a selective nicotinic acetylcholine receptoragonist, antagonizes MK-801 –elicited mouse popping behavior, an animal model ofschizophrenia. Behavioural Brain Research 2004; 153(2): 419-422.Millan MJ. N-methyl-D-aspartate receptors as a target for improved antipsychotic agents:novel insights and clinical perspectives. Psychopharmacology 2005; 179: 30-53.Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmissionby ketamine: a novel step in the pathway from NMDA receptor blockade todopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal ofNeuroscience 1997; 17(8): 2921-2927.Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR, Kleinman JE.Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and controlbrains. Synapse 1997; 27: 168-176.Norris DO, Mastropaolo J, O'Connor DA, Novitzki MR, Deutsch SI. Glycinergicinterventions potentiate the ability of MK-801 to raise the threshold voltage for tonichindlimb extension in mice. Pharmacology Biochemistry and Behavior 1992; 43(1): 609-612.Norris DO, Mastropaolo J, O'Connor DA, Cohen JM, and Deutsch SI. A glycinergicintervention potentiates the antiseizure efficacies of MK-801, flurazepam, andcarbamazepine. Neurochemical Research 1994; 19(2): 161-165.Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Archives ofGeneral Psychiatry 1995; 52: 998-1007.Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neuronsby phencyclidine and related drugs. Science 1989; 244: 1360-1362.Robertson GS, Matsumura H, Fibiger HC.Induction patterns of Fos-like immunoreactivity inthe forebrain as predictors of atypical antipsychotic activity. Journal of Pharmacologyand Experimental Therapeutics 1994; 271(2): 1058-1066.Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI.Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: anopen-label, pilot. Clinical Neuropharmacology 1989; 12(5): 416-424.Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI. An open-label trial ofmilacemide in schizophrenia: An NMDA intervention strategy. ClinicalNeuropharmacology 1990: 13(4): 348-354.Rosse RB, Schwartz BL, Davis RE, Deutsch SI. An NMDA intervention strategy inschizophrenia with “low dose” milacemide. Clinical Neuropharmacology 1991; 14(3):268-272.Rosse RB, Schwartz BL, Zlotolow S, Banay-Schwartz M, Trinidad AC, Peace TD, DeutschSI. Effects of a low-tryptophan diet as an adjuvant to conventional neuroleptic therapy inschizophrenia. Clinical Neuropharmacology 1992; 15(2): 129-141.Rosse RB, Mastropaolo J, Koetzner L, Morn CB, Sussman DM, Deutsch SI. Computerizedmeasurement of MK-801 – elicited hyperactivity and popping in mice. ClinicalNeuropharmacology 1995; 18: 448-457.Rosse RB, McCarthy M, Kendrick K, Deutsch SI. D-Cycloserine adjuvant therapy tomolindone in the treatment of schizophrenia. Clinical Neuropharmacology 1996; 19(5):444-450.